Neovacs in Paris (France) investigates immunotherapies for the treatment of autoimmune diseases and today signed a partnering agreement with the molluscan protein manufacturer, Stellar Biotechnologies (US).
This joint venture will operate under the name of Neostell SAS, and it will be owned 30:70, the majority going to Neovacs. Neovacs is a biotech focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and (or) inflammatory diseases.
Stellar, on the other hand, is a sustainable manufacturer of Keyhole Limpet Hemocyanin (KLH), an oxygen carrier protein naturally obtained from the Keyhole Limpet (Megathura crenulata).
KLH is used as both a finished product for measuring immune status, as well as the active pharmaceutical ingredient (API) in a wide range of immunotherapies (targeting cancer, immune disorders, Alzheimer’s, and inflammatory diseases).
We met the CEO of Neovacs, Miguel Sieler, at BIO-Europe in November. Sieler explained how their kinoids are used to stimulate a polyclonal antibody response to a specific cytokine used (depending on the indication targeted).